Gasmi Mehdi 4
4 · Adverum Biotechnologies, Inc. · Filed Jul 22, 2020
Insider Transaction Report
Form 4
Gasmi Mehdi
VP, Pharmaceutical Development
Transactions
- Sale
Common Stock
2020-07-20$17.60/sh−5,000$87,978→ 274,442 total - Exercise/Conversion
Common Stock
2020-07-20$4.80/sh+5,000$24,000→ 279,442 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-07-20−5,000→ 78,000 totalExercise: $4.80Exp: 2026-02-11→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.26 to $18.24. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Fully vested and exercisable.